Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoflurane + sufentanil is a combination of two anesthetic agents used together to induce and maintain general anesthesia, particularly in major surgeries such as cardiac surgery. Isoflurane is a volatile inhalational anesthetic that acts primarily by enhancing inhibitory neurotransmission via gamma-aminobutyric acid (GABA) receptors in the central nervous system, leading to loss of consciousness and amnesia. Sufentanil is a potent synthetic opioid analgesic that acts as an agonist at the μ-opioid receptor, providing profound analgesia and contributing to hemodynamic stability during surgery. The combination allows for balanced anesthesia—isoflurane provides hypnosis while sufentanil offers strong analgesia—resulting in reduced stress response to surgical stimuli, stable cardiovascular parameters, and potentially faster recovery compared with higher doses of either agent alone[1][3][5]. This regimen is commonly used in settings requiring deep anesthesia with controlled hemodynamics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoflurane + sufentanil.